<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to the page on antihypertensives and diuretics!</h1>
        <p id="welcome-description">Explore the following topics to enhance your knowledge.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Antihypertensives and Diuretics</h1>
        <p><strong>Hypertension</strong>, defined as a sustained blood pressure ≥140/90 mmHg, is one of the most prevalent modifiable risk factors for cardiovascular disease worldwide. The regulation of blood pressure is a complex interplay between <strong>cardiac output</strong> and <strong>systemic vascular resistance</strong>, governed by the <strong>renin-angiotensin-aldosterone system (RAAS)</strong>, sympathetic nervous system, and renal sodium handling.</p>

        <h2>Historical Perspective</h2>
        <p>The treatment of hypertension has evolved remarkably since the 1950s when the first effective antihypertensives (ganglionic blockers) were introduced. The development of <strong>thiazide diuretics</strong> in the late 1950s marked a turning point, proving that blood pressure control could prevent cardiovascular complications. The subsequent introduction of <strong>beta-blockers</strong>, <strong>calcium channel blockers</strong>, and <strong>RAAS inhibitors</strong> has transformed hypertension management.</p>

        <h2>Renal Physiology and Blood Pressure Regulation</h2>
        <p>The kidneys play a pivotal role in long-term blood pressure regulation through:</p>
        <ol>
            <li><strong>Pressure natriuresis:</strong> Increased arterial pressure leads to enhanced sodium and water excretion</li>
            <li><strong>RAAS activation:</strong> Decreased renal perfusion pressure stimulates renin release from juxtaglomerular cells</li>
            <li><strong>Tubuloglomerular feedback:</strong> Macula densa cells sense NaCl delivery to the distal tubule</li>
        </ol>

        <h2>Vascular Physiology</h2>
        <p>Vascular smooth muscle tone is primarily regulated by:</p>
        <ol>
            <li><strong>Calcium-dependent contraction:</strong> Via L-type calcium channels</li>
            <li><strong>Sympathetic input:</strong> α<sub>1</sub>-adrenergic receptors mediate vasoconstriction</li>
            <li><strong>Endothelial factors:</strong> Nitric oxide (vasodilation) and endothelin (vasoconstriction)</li>
        </ol>

        <div class="mnemonic">
            <strong>Mnemonic: "RAAS the Pressure"</strong> - Remember the key components of blood pressure regulation:<br>
            <strong>R</strong>enin release<br>
            <strong>A</strong>ngiotensin II<br>
            <strong>A</strong>ldosterone<br>
            <strong>S</strong>ympathetic tone
        </div>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which of the following is NOT a primary mechanism of blood pressure regulation?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Pressure natriuresis</li>
            <li data-answer="wrong">Renin-angiotensin-aldosterone system</li>
            <li data-answer="correct">Hepatic gluconeogenesis</li>
            <li data-answer="wrong">Sympathetic nervous system activity</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>The juxtaglomerular apparatus releases renin in response to:</p>
        <ul class="options" id="options">
            <li data-answer="correct">Decreased afferent arteriolar pressure</li>
            <li data-answer="wrong">Increased angiotensin II levels</li>
            <li data-answer="wrong">Hypernatremia</li>
            <li data-answer="wrong">Elevated serum potassium</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>RAAS Inhibitors: ACE Inhibitors and ARBs</h1>
        <h2>Mechanism of Action</h2>
        <p><strong>ACE inhibitors</strong> (e.g., lisinopril, enalapril) block the conversion of angiotensin I to angiotensin II by inhibiting angiotensin-converting enzyme (ACE), while <strong>ARBs</strong> (e.g., losartan, valsartan) competitively block the AT<sub>1</sub> receptor. This results in:</p>
        <ol>
            <li>Reduced vasoconstriction</li>
            <li>Decreased aldosterone secretion (reducing sodium retention)</li>
            <li>Increased bradykinin levels (ACE inhibitors only)</li>
        </ol>

        <h2>Indications</h2>
        <p>RAAS inhibitors are first-line for:</p>
        <ol>
            <li>Hypertension (especially in diabetes or proteinuria)</li>
            <li>Heart failure with reduced ejection fraction</li>
            <li>Post-myocardial infarction</li>
            <li>Diabetic nephropathy</li>
        </ol>

        <h2>Side Effects</h2>
        <p>ACE inhibitors may cause:</p>
        <ol>
            <li><strong>Dry cough</strong> (bradykinin-mediated, in 5-20% of patients)</li>
            <li><strong>Angioedema</strong> (rare but potentially life-threatening)</li>
            <li><strong>Hyperkalemia</strong> (due to reduced aldosterone)</li>
            <li><strong>Teratogenicity</strong> (contraindicated in pregnancy)</li>
        </ol>
        <p>ARBs generally have better tolerability with lower cough risk.</p>

        <h2>Pharmacokinetics</h2>
        <p>Most ACE inhibitors (except lisinopril and captopril) are prodrugs requiring hepatic activation. ARBs are primarily metabolized by CYP2C9. Dosage adjustment is needed in renal impairment.</p>

        <div class="mnemonic">
            <strong>Mnemonic: "ACE Cough"</strong> - Remember the distinctive side effects:<br>
            <strong>A</strong>ngioedema<br>
            <strong>C</strong>ough<br>
            <strong>E</strong>levated potassium
        </div>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>A 58-year-old woman develops a persistent dry cough after starting lisinopril. What is the most appropriate next step?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Add a antitussive medication</li>
            <li data-answer="correct">Switch to an ARB</li>
            <li data-answer="wrong">Continue therapy and monitor</li>
            <li data-answer="wrong">Discontinue all antihypertensives</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>Which patient is the BEST candidate for ACE inhibitor therapy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">A 32-year-old pregnant woman with hypertension</li>
            <li data-answer="correct">A 65-year-old man with diabetes and proteinuria</li>
            <li data-answer="wrong">A 70-year-old woman with bilateral renal artery stenosis</li>
            <li data-answer="wrong">A 45-year-old man with a history of hereditary angioedema</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Calcium Channel Blockers</h1>
        <h2>Classification</h2>
        <p>Calcium channel blockers (CCBs) are divided into:</p>
        <ol>
            <li><strong>Dihydropyridines</strong> (nifedipine, amlodipine): Predominantly vascular selective</li>
            <li><strong>Non-dihydropyridines</strong> (verapamil, diltiazem): Cardiac and vascular effects</li>
        </ol>

        <h2>Mechanism of Action</h2>
        <p>CCBs block L-type calcium channels, leading to:</p>
        <ol>
            <li>Vascular smooth muscle relaxation (reduced systemic vascular resistance)</li>
            <li>Cardiac effects (non-DHPs only): Negative inotropy and chronotropy</li>
        </ol>

        <h2>Clinical Uses</h2>
        <p>Dihydropyridines are preferred for hypertension, while non-DHPs are used for:</p>
        <ol>
            <li>Rate control in atrial fibrillation</li>
            <li>Vasospastic angina</li>
            <li>Hypertrophic cardiomyopathy (verapamil)</li>
        </ol>

        <h2>Adverse Effects</h2>
        <p>Dihydropyridines may cause:</p>
        <ol>
            <li>Peripheral edema (dose-dependent)</li>
            <li>Reflex tachycardia (short-acting formulations)</li>
            <li>Gingival hyperplasia</li>
        </ol>
        <p>Non-DHPs can cause:</p>
        <ol>
            <li>Bradycardia</li>
            <li>Constipation (especially verapamil)</li>
            <li>Heart block (contraindicated in 2nd/3rd degree AV block)</li>
        </ol>

        <div class="mnemonic">
            <strong>Mnemonic: "DHP vs Non-DHP"</strong> - Remember the key differences:<br>
            <strong>D</strong>ihydropyridines = <strong>D</strong>ilate vessels<br>
            <strong>N</strong>on-DHPs = <strong>N</strong>egative cardiac effects
        </div>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>A 72-year-old man with hypertension develops bilateral leg edema on amlodipine. What is the most likely mechanism?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Increased capillary permeability</li>
            <li data-answer="correct">Preferential arteriolar over venular dilation</li>
            <li data-answer="wrong">Right heart failure</li>
            <li data-answer="wrong">Hypoalbuminemia</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>Which calcium channel blocker is contraindicated in a patient with 2nd degree AV block?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Amlodipine</li>
            <li data-answer="correct">Verapamil</li>
            <li data-answer="wrong">Nifedipine</li>
            <li data-answer="wrong">Felodipine</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Beta-Adrenergic Blockers</h1>
        <h2>Classification</h2>
        <p>Beta-blockers are categorized by:</p>
        <ol>
            <li><strong>Cardioselectivity</strong> (β<sub>1</sub> preference): Metoprolol, atenolol</li>
            <li><strong>Intrinsic sympathomimetic activity</strong>: Pindolol, acebutolol</li>
            <li><strong>Additional α-blockade</strong>: Carvedilol, labetalol</li>
        </ol>

        <h2>Mechanisms</h2>
        <p>Beta-blockers reduce blood pressure through:</p>
        <ol>
            <li>Decreased cardiac output (reduced heart rate and contractility)</li>
            <li>Reduced renin release (β<sub>1</sub> effect on juxtaglomerular cells)</li>
            <li>Central sympathetic outflow reduction</li>
        </ol>

        <h2>Clinical Uses</h2>
        <p>Indications include:</p>
        <ol>
            <li>Hypertension (though no longer first-line for uncomplicated cases)</li>
            <li>Coronary artery disease</li>
            <li>Heart failure (carvedilol, metoprolol succinate, bisoprolol)</li>
            <li>Arrhythmias</li>
        </ol>

        <h2>Adverse Effects</h2>
        <p>Common issues include:</p>
        <ol>
            <li>Fatigue and exercise intolerance</li>
            <li>Bronchoconstriction (non-selective agents)</li>
            <li>Masking of hypoglycemia symptoms</li>
            <li>Erectile dysfunction</li>
        </ol>

        <div class="mnemonic">
            <strong>Mnemonic: "Beta Blockers BAD HEART"</strong> - Key contraindications/precautions:<br>
            <strong>B</strong>radycardia<br>
            <strong>A</strong>sthma/COPD<br>
            <strong>D</strong>ecompensated heart failure<br>
            <strong>H</strong>ypoglycemia (in diabetics)<br>
            <strong>E</strong>lectric conduction defects<br>
            <strong>A</strong>cute MI (avoid abrupt withdrawal)<br>
            <strong>R</strong>aynaud's phenomenon<br>
            <strong>T</strong>iredness
        </div>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>Which beta-blocker is most appropriate for a patient with both hypertension and COPD?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Propranolol</li>
            <li data-answer="correct">Metoprolol</li>
            <li data-answer="wrong">Carvedilol</li>
            <li data-answer="wrong">Nadolol</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>What is the mechanism by which beta-blockers reduce blood pressure in the long term?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Direct vasodilation</li>
            <li data-answer="correct">Reduced renin secretion</li>
            <li data-answer="wrong">Increased sodium excretion</li>
            <li data-answer="wrong">Enhanced nitric oxide production</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Diuretics: Thiazides and Thiazide-like Agents</h1>
        <h2>Mechanism of Action</h2>
        <p>Thiazides (e.g., hydrochlorothiazide) and thiazide-like diuretics (e.g., chlorthalidone, indapamide) inhibit the <strong>Na<sup>+</sup>-Cl<sup>-</sup> symporter</strong> in the distal convoluted tubule, leading to:</p>
        <ol>
            <li>Increased sodium and water excretion</li>
            <li>Initial plasma volume reduction</li>
            <li>Long-term reduction in peripheral vascular resistance (mechanism unclear)</li>
        </ol>

        <h2>Clinical Uses</h2>
        <p>Thiazides are first-line for uncomplicated hypertension, especially in:</p>
        <ol>
            <li>Black patients (per JNC guidelines)</li>
            <li>Elderly patients</li>
            <li>Patients with osteoporosis (calcium-sparing effect)</li>
        </ol>

        <h2>Adverse Effects</h2>
        <p>Important side effects include:</p>
        <ol>
            <li><strong>Hypokalemia</strong> (due to increased distal Na<sup>+</sup> delivery)</li>
            <li><strong>Hyperuricemia</strong> (may precipitate gout)</li>
            <li><strong>Hypercalcemia</strong> (reduced calcium excretion)</li>
            <li><strong>Hyperglycemia</strong> (insulin resistance)</li>
        </ol>

        <div class="mnemonic">
            <strong>Mnemonic: "THIAZIDE"</strong> - Key side effects:<br>
            <strong>T</strong>hyponatremia<br>
            <strong>H</strong>ypokalemia<br>
            <strong>I</strong>mpotence<br>
            <strong>A</strong>rrhythmia (from hypokalemia)<br>
            <strong>Z</strong>ero magnesium (hypomagnesemia)<br>
            <strong>I</strong>nsulin resistance<br>
            <strong>D</strong>yslipidemia (mild)<br>
            <strong>E</strong>levated uric acid
        </div>
    </div>

    <div class="question-card">
        <h1>Question 9</h1>
        <p>A 68-year-old man on hydrochlorothiazide develops weakness. Serum potassium is 2.8 mEq/L. What is the most appropriate next step?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Discontinue hydrochlorothiazide</li>
            <li data-answer="correct">Prescribe potassium supplementation</li>
            <li data-answer="wrong">Start spironolactone</li>
            <li data-answer="wrong">Administer intravenous calcium</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 10</h1>
        <p>Which electrolyte abnormality is LEAST likely with chronic thiazide use?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Hypokalemia</li>
            <li data-answer="wrong">Hyponatremia</li>
            <li data-answer="correct">Hypocalcemia</li>
            <li data-answer="wrong">Hypomagnesemia</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Loop Diuretics</h1>
        <h2>Mechanism of Action</h2>
        <p>Loop diuretics (e.g., furosemide, bumetanide, torsemide) inhibit the <strong>Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> symporter</strong> in the thick ascending limb of Henle, resulting in:</p>
        <ol>
            <li>Profound natriuresis and diuresis (15-25% of filtered Na<sup>+</sup> excreted)</li>
            <li>Reduced medullary interstitial tonicity (impairs urinary concentrating ability)</li>
            <li>Increased calcium and magnesium excretion</li>
        </ol>

        <h2>Clinical Uses</h2>
        <p>Primary indications include:</p>
        <ol>
            <li>Edematous states (heart failure, cirrhosis, nephrotic syndrome)</li>
            <li>Acute pulmonary edema</li>
            <li>Hypercalcemia</li>
            <li>Resistant hypertension (in combination with thiazides)</li>
        </ol>

        <h2>Adverse Effects</h2>
        <p>Important complications:</p>
        <ol>
            <li><strong>Hypokalemia</strong> (more severe than with thiazides)</li>
            <li><strong>Ototoxicity</strong> (especially with rapid IV administration)</li>
            <li><strong>Hyperuricemia</strong></li>
            <li><strong>Hypovolemia</strong> and prerenal azotemia</li>
        </ol>

        <div class="mnemonic">
            <strong>Mnemonic: "LOOP"</strong> - Key features:<br>
            <strong>L</strong>asts short (short half-life)<br>
            <strong>O</strong>totoxicity risk<br>
            <strong>O</strong>vercomes thiazide resistance<br>
            <strong>P</strong>otassium wasting
        </div>
    </div>

    <div class="question-card">
        <h1>Question 11</h1>
        <p>Which of the following is a characteristic feature distinguishing loop diuretics from thiazides?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Calcium-sparing effect</li>
            <li data-answer="correct">Ability to increase calcium excretion</li>
            <li data-answer="wrong">Primary site of action in distal tubule</li>
            <li data-answer="wrong">Use in diabetes insipidus</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 12</h1>
        <p>A patient with heart failure develops hearing loss after IV furosemide. What is the most likely mechanism?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Allergic reaction</li>
            <li data-answer="correct">Ototoxicity from stria vascularis damage</li>
            <li data-answer="wrong">Cochlear ischemia</li>
            <li data-answer="wrong">Drug interaction with aminoglycosides</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Potassium-Sparing Diuretics</h1>
        <h2>Classification</h2>
        <p>Potassium-sparing diuretics include:</p>
        <ol>
            <li><strong>Aldosterone antagonists</strong> (spironolactone, eplerenone)</li>
            <li><strong>Direct ENaC inhibitors</strong> (amiloride, triamterene)</li>
        </ol>

        <h2>Mechanisms</h2>
        <p>These agents act on the collecting duct:</p>
        <ol>
            <li>Aldosterone antagonists block mineralocorticoid receptors</li>
            <li>ENaC inhibitors block the epithelial sodium channel</li>
            <li>Both reduce potassium excretion by decreasing lumen-negative potential</li>
        </ol>

        <h2>Clinical Uses</h2>
        <p>Important indications:</p>
        <ol>
            <li>Heart failure (especially spironolactone in reduced EF)</li>
            <li>Primary hyperaldosteronism</li>
            <li>Adjuvant in thiazide/loop diuretic therapy to prevent hypokalemia</li>
            <li>Resistant hypertension</li>
        </ol>

        <h2>Adverse Effects</h2>
        <p>Key concerns:</p>
        <ol>
            <li><strong>Hyperkalemia</strong> (especially with renal impairment or ACEI/ARB use)</li>
            <li><strong>Gynecomastia</strong> (spironolactone, due to antiandrogen effects)</li>
            <li><strong>Metabolic acidosis</strong> (amiloride/triamterene)</li>
        </ol>

        <div class="mnemonic">
            <strong>Mnemonic: "SPIRONOLACTONE"</strong> - Key features:<br>
            <strong>S</strong>aves potassium<br>
            <strong>P</strong>otassium-sparing<br>
            <strong>I</strong>nhibits aldosterone<br>
            <strong>R</strong>educes mortality in CHF<br>
            <strong>O</strong>ffers antiandrogen effects<br>
            <strong>N</strong>o hyperkalemia with normal renal function<br>
            <strong>O</strong>ften combined with loop diuretics<br>
            <strong>L</strong>ow dose effective in primary hyperaldosteronism<br>
            <strong>A</strong>void in pregnancy<br>
            <strong>C</strong>auses gynecomastia<br>
            <strong>T</strong>reats ascites in cirrhosis<br>
            <strong>O</strong>ne of few diuretics that improve survival<br>
            <strong>N</strong>eeds monitoring of potassium<br>
            <strong>E</strong>plerenone is more selective alternative
        </div>
    </div>

    <div class="question-card">
        <h1>Question 13</h1>
        <p>Which patient is at highest risk for complications from spironolactone therapy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">A 45-year-old woman with normal renal function</li>
            <li data-answer="correct">A 70-year-old man with CKD stage 3 on lisinopril</li>
            <li data-answer="wrong">A 60-year-old woman with primary hyperaldosteronism</li>
            <li data-answer="wrong">A 50-year-old man with compensated cirrhosis</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 14</h1>
        <p>What is the mechanism by which amiloride reduces potassium excretion?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Aldosterone receptor blockade</li>
            <li data-answer="correct">Inhibition of apical sodium channels</li>
            <li data-answer="wrong">Increased proximal tubule sodium reabsorption</li>
            <li data-answer="wrong">Stimulation of basolateral Na<sup>+</sup>/K<sup>+</sup> ATPase</li>
        </ul>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>